Dentist Faces DEA Hammer in Drug Prescribing Showdown
Published Date: 10/30/2025
Notice
Summary
Dr. Lawrence Michael Willis from Colorado lost his DEA registration because he didn’t follow state rules about checking the Prescription Drug Monitoring Program. He didn’t ask for a hearing in time, so the government revoked his registration by default. This means he can’t legally handle controlled substances anymore, effective immediately, which could impact his dental practice and income.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked; Colorado Renewals Denied
The DEA revoked Lawrence Michael Willis's Certificate of Registration No. AW1335822 and denied any pending applications to renew or modify that registration as well as any other pending application for additional registration in Colorado. The Agency found he failed to register for and query the Colorado Prescription Drug Monitoring Program and issued at least 195 opioid and benzodiazepine prescriptions without querying the PDMP between July 2018 and June 2023. The revocation and denials are effective December 1, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19704 — Committee and Quarterly Board Meetings
The National Assessment Governing Board is holding its committee and quarterly meetings in person and online on November 20-21, 2025. Anyone interested must register online five days before the meetings to join virtually. These meetings let the public learn about and comment on important education policies, with no new costs or major changes announced.
Next: 2025-19707 — Dawn Evert, N.P.; Decision and Order
Dawn Evert, a nurse practitioner from Colorado, had her DEA registration suspended and then revoked because she prescribed dangerous drugs without proper medical reasons or monitoring. This decision protects public safety by stopping her from legally prescribing controlled substances. The revocation is final, even though her registration expired in August 2025, so she can’t prescribe these drugs anymore.